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Assessing and Comparing the Performance of Molecular
Diagnostic Tests
Timothy J. O’LearyFrom the Ofﬁce of Research and Development, Department of Veterans Affairs, Washington, District of Colombia (Editor-in-Chief)Disclaimer: The views or opinions expressed in this editorial are those of
the author and are not to be construed as ofﬁcial, or as representing the
views of the Department of Veterans Affairs.Many papers submitted to The Journal of Molecular Di-
agnostics (JMD) are designed to examine either of two spe-
ciﬁc concepts: to determine the sensitivity and speciﬁcity of a
test or to compare two or more tests. Although inspection of
raw data is an important part of the scientiﬁc process, there is
a substantial likelihood that, without appropriate statistical
analysis, a laboratorian may draw stronger conclusions than
are justiﬁed by the experimental design or the data. As
Editor-in-Chief of JMD, I have worked with the Associate
Editors to increase the rigor of data analysis and evaluation
during the review process1 with the ultimate goal of im-
proving the accuracy of the conclusions reported.
Choosing (and Using) Statistics Appropriately
Data analysis is complicated by the wide variation in com-
parisons that may be performed. For example, there may be a
perfect standard to which two different methods are compared.
Or, twomethods, neither of which is perfect, may be compared
with each other. The appropriate experimental designs for
these two situations are different, and determining the correct
approach to comparing the two methods is more complex than
is appreciated bymost laboratorians or evenmany statisticians.
The abundance of statistical and clinical literature does not
simplify the problem for nonstatisticians, although excellent
online resources are available from the American Statistical
Association (Assessing Agreement for Diagnostic Devices,
http://www.amstat.org/meetings/fdaworkshop/presentations/
2006/Assessing%20Agreement%20for%20diagnostic%20
tests%202006.ppt, last accessed November 3, 2013) and by
the US Food and Drug Administration (Guidance for Industry
and FDA Staff: Statistical Guidance on Reporting Results from
Studies Evaluating Diagnostic Tests, http://www.fda.gov/
downloads/MedicalDevices/DeviceRegulationandGuidance/
GuidanceDocuments/ucm071287.pdf, last accessed November
3, 2013).Copyright ª 2014 American Society for Investigative Pathology
and the Association for Molecular Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.jmoldx.2013.11.002Through careful editorial review and the increasing use of
statistical reviewers, we at the JMD have attempted to
eliminate some of the sources of potentially erroneous
conclusions, such as the use of discrepant analysis (which is
both scientiﬁcally unjustiﬁable and widely used).2 We have
also required publication of conﬁdence intervals for con-
cordance, sensitivity, speciﬁcity, and similar quantities, and
the Editors try to guarantee that these conﬁdence intervals
appear at every appropriate location within a manuscript,
including the abstract, to ensure that readers understand the
limitations of the experiments that are reported. We also
require the use of a Bonferroni correction (MathWorldeA
Wolfram Web Resource, http://mathworld.wolfram.com/
BonferroniCorrection.html, last accessed November 18,
2013) for multiple hypothesis testing where appropriate.
We regularly emphasize to authors that performance
characteristics for laboratory tests that have been calculated
using the same cases used to establish cutoffs and threshold
invariably inﬂate the apparent sensitivity and speciﬁcity,
requiring the use of an independent validation set if
reporting is to be accurate. In so doing we believe we have
reduced the number of errors in the ways authors interpret
their data and have provided information in JMD by which
readers can more readily interpret the signiﬁcance of re-
ported results. Although these efforts signiﬁcantly increase
editorial burden, and often increase the number of revisions
required before a paper can be accepted for publication, we
believe these efforts have reduced the probability that the
papers we publish have a greater Type I error rate than that
expected by the use of P < 0.05 for the assessment of
statistical signiﬁcance e a value that guarantees that about
1 in 20 conclusions reported will be incorrect on the basis of
chance alone.
EditorialEvaluating Comparisons Properly
These efforts have not even attempted to address some of the
other sources of error that authors may introduce into their
manuscripts. Foremost among these is the Type 2 error, the
failure to identify a difference in test performance when such a
difference, in fact, exists. The most common cause of Type 2
error is an insufﬁcient number of cases included in comparison
studies. While JMD does not intend to require the use of a
power analysis as part of its publication policy, we will not
allow a conclusion of equivalence (or of noninferiority) to be
drawn in the absence of such an analysis. When a power
analysis is presented, it should clearly be stated whether the
sample sizes used in the comparison were determined on the
basis of a power analysis undertaken before the onset of
experimentation, or if the power was instead estimated at the
end of an experiment in which sample size was determined by
some other method (such as specimen availability). Several
online tools for computing sample sizes are available for this
purpose [StatsToDo Trading Pty Ltd, https://www.statstodo.
com/SSizSenSpc_Pgm.php (sample size for sensitivity and
speciﬁcity) and https://www.statstodo.com/SSizMcNemar_
Pgm.php (sample size for McNemar test, ie for paired sam-
ples) last accessed November 3, 2013].
If one performs a few power calculations using the statistical
powers usually required for deﬁnitive clinical trials e 0.8 to
0.9 e one ﬁnds that the required sample sizes are much larger
than those typically reported in papers published in JMD or
other diagnostic journals. It is thus no surprise that the conﬁ-
dence intervals for diagnostic sensitivity and speciﬁcity typi-
cally reported in JMD are quite wide. When conﬁdence
intervals are wide, it is difﬁcult to determine how much better
one test is versus another. For this reason, it is appropriate to
use a sufﬁciently large sample size to demonstrate that test
performancee at the lowest limit of sensitivity and speciﬁcity
allowed by the computed conﬁdence limits e appears to have
diagnostic value to a well trained individual.
The use of complex mathematical calculations based on
numerous variables provides yet another set of potential errors
that are unlikely to be detected in ordinary editorial review.
Generally speaking, reviewers and readers are not privy to
computer codes, the algorithms upon which the computer
codes were based, training data, or validation data. In at least
one famous case, this resulted in numerous publications3e5
with serious errors that were only discovered with extraordi-
nary effort on the part of two statisticians who were unable to
replicate the initial results using their own data.6 These stat-
isticians have subsequently recommended broad public
availability of code and data, so that independent validation2can be achieved.7 Although the appeal of such an approach is
strong, JMD has not adopted such an editorial requirement.
Nevertheless, we strongly urge authors to make this infor-
mation available when possible, and the Editors reserve the
right to require that it be made available as part of the editorial
review process. In addition, the Editors may require authors to
make this information available to one or more independent
parties, under appropriate data usage agreements, to guarantee
the reproducibility and integrity of published reports.Practical Improvements
All of us at JMD are committed to publishing articles that meet
the highest standards of scientiﬁc rigor, including statistical
assessment. To this end, we will be increasing the level of
statistical review and employing professional statisticians as
necessary because results published in JMD often form the
basis of laboratory-developed tests and in vitro diagnostic
devices used in clinical care. The changes that we suggest will
ensure that laboratorians who transform into practice the
concepts appearing in the Journal are sufﬁciently well
informed to make good choices on behalf of their patients.References
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